INNOVATE Corp.
Close on Oct 19, 2026
- Market cap
- $83.11M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $421.60M | $0.71 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $364.80M | $-1.29 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | $382.70M | $-0.58 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $347.10M | $-0.71 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $242.00M | $-1.67 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $274.20M | $-1.89 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | $236.60M | $-1.29 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $242.20M | $-1.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 4, 2024 | After market close | – | – | – |
Press releases
Announcements Innovate filed with the SEC
INNOVATE Completes Sale of DBM Global to IES Holdings
Material agreement · Agreement terminated · Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Announces Closing of the Sale of a Controlling Interest in its Broadcasting Segment to CONX
Material agreement · Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
MediBeacon ® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology
Other events · EX-99.1 to Form 8-K
INNOVATE Agrees to $650 Million Sale of DBM Global to IES Holdings
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA FINANCIAL STATEMENTS
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
INNOVATE Corp. Announces Second Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. 2026 INNOVATE Corp. Q2 2026 Earnings Release Supplement August 6, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend
Other events · EX-99.1 to Form 8-K
INNOVATE Announces Successful Closing of Broadcasting Refinancing and Agrees to Partial Sale of Broadcasting
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. Announces First Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. 2026 INNOVATE Corp. Q1 2026 Earnings Release Supplement May 14, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend
Other events · EX-99.1 to Form 8-K
MediBeacon ® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation
Other events · EX-99.1 to Form 8-K
INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. 2026 INNOVATE Corp. Q4 2025 Earnings Release Supplement March 26, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)
Other events · EX-99.1 to Form 8-K
INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend
Other events · EX-99.1 to Form 8-K
MediBeacon® Next Generation TGFR TM System Receives FDA Approval
Other events · EX-99.1 to Form 8-K
INNOVATE Corp. Announces Third Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. 2025 INNOVATE Corp. Q3 2025 Earnings Release Supplement November 12, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MediBeacon receives regulatory approval to sell the Transdermal GFR System in China
Other events · EX-99.1 to Form 8-K
INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend
Other events · EX-99.1 to Form 8-K
INNOVATE’s Portfolio Company, R2, has Explosive Growth and Global Reach with Glacial ® Skin Continuing to Redefine Aesthetic Innovation
Other events · EX-99.1 to Form 8-K
INNOVATE Corp. Announces Second Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. 2025 INNOVATE Corp. Q2 2025 Earnings Release Supplement August 5, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
INNOVATE Announces Early Results of Exchange Offer of Senior Secured Notes and Solicitation of Consents
Other events · EX-99.1 to Form 8-K
INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend
Other events · EX-99.1 to Form 8-K
INNOVATE Launches Indebtedness Refinancing Transactions
Material agreement · Other events · EX-99.1 to Form 8-K
INNOVATE’s Portfolio Company DBM Global To Pay Cash Dividend
Other events · EX-99.1 to Form 8-K
DBM GLOBAL ENTERS INTO AN AMENDED AND RESTATED CREDIT AGREEMENT
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. Announces First Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. ™ 2025 INNOVATE Corp. Q1 2025 Earnings Release Supplement May 6, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. ™ 2025 INNOVATE Corp. Q4 2024 Earnings Release Supplement March 31, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MediBeacon® Transdermal GFR System receives device approval in China
Other events · EX-99.1 to Form 8-K
MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function
Other events · EX-99.1 to Form 8-K
INNOVATE Corp. Announces Third Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
INNOVATE Corp. ™ 2024 INNOVATE Corp. Q3 2024 Earnings Release Supplement November 6, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
INNOVATE Corp. Regains Compliance with NYSE Minimum Price Requirement
Other events · EX-99.1 to Form 8-K